Immuneering Corporation Debt Securities Available For Sale Excluding Accrued Interest
Immuneering Corporation (IMRX) had Debt Securities Available For Sale Excluding Accrued Interest of $141.35 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest · last filed 2026-08-05
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest $141.35M.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest $151.32M.
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest $88.37M.
- 2024-12-31: Debt Securities Available For Sale Excluding Accrued Interest $0.00.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest |
|---|---|
| 2026-06-30 | $141.35M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $151.32M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $88.37M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |